These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25600478)

  • 1. Non-alcoholic fatty liver disease: today and tomorrow.
    Abenavoli L
    Rev Recent Clin Trials; 2014; 9(3):125. PubMed ID: 25600478
    [No Abstract]   [Full Text] [Related]  

  • 2. [S2k Guideline non-alcoholic fatty liver disease].
    Roeb E; Steffen HM; Bantel H; Baumann U; Canbay A; Demir M; Drebber U; Geier A; Hampe J; Hellerbrand C; Pathil-Warth A; Schattenberg JM; Schramm C; Seitz HK; Stefan N; Tacke F; Tannapfel A; Lynen Jansen P; Bojunga J
    Z Gastroenterol; 2015 Jul; 53(7):668-723. PubMed ID: 26167698
    [No Abstract]   [Full Text] [Related]  

  • 3. [Strengthen researches on risk factors and early diagnosis of nonalcoholic fatty liver].
    Li YM
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):805-7. PubMed ID: 24516924
    [No Abstract]   [Full Text] [Related]  

  • 4. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.
    Abenavoli L; Milic N; Peta V; Alfieri F; De Lorenzo A; Bellentani S
    World J Gastroenterol; 2014 Dec; 20(45):16831-40. PubMed ID: 25492997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Non-alcoholic Fatty Liver Disease.
    Uppal V; Mansoor S; Furuya KN
    Curr Gastroenterol Rep; 2016 May; 18(5):24. PubMed ID: 27086005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NASH, from diagnosis to treatment: Where do we stand?
    Harrison SA
    Hepatology; 2015 Dec; 62(6):1652-5. PubMed ID: 26446314
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
    Argyrou C; Moris D; Vernadakis S
    J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D: a new player in non-alcoholic fatty liver disease?
    Eliades M; Spyrou E
    World J Gastroenterol; 2015 Feb; 21(6):1718-27. PubMed ID: 25684936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Alcoholic Fatty Liver Disease in HIV Infection.
    Macías J; Pineda JA; Real LM
    AIDS Rev; 2017; 19(1):35-46. PubMed ID: 28182612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease.
    Pearce L
    Nurs Stand; 2016 Aug; 30(52):15. PubMed ID: 27641564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease.
    Byrne CD; Targher G
    Gastroenterology; 2016 Jan; 150(1):7-10. PubMed ID: 26602219
    [No Abstract]   [Full Text] [Related]  

  • 12. [Value of ANI in differentiating between alcoholic liver disease and nonalcoholic fatty liver disease].
    Wang J; Li P; Jiang Z; Yang Q; Liu Y; Shi R; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):136-9. PubMed ID: 26983484
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.
    Castera L
    Liver Int; 2018 Feb; 38 Suppl 1():67-70. PubMed ID: 29427494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future trends in the treatment of non-alcoholic steatohepatitis.
    Fiorucci S; Biagioli M; Distrutti E
    Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.
    Mitsiou E; Boutari C; Kotsis V; Georgianou E; Doumas M; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2018; 16(4):393-400. PubMed ID: 28669329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
    Athyros VG; Katsiki N; Doumas M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
    [No Abstract]   [Full Text] [Related]  

  • 17. [Fatty liver, alcoholic steatohepatitis, and non-alcoholic steatohepatitis].
    Bernal-Reyes R
    Rev Gastroenterol Mex; 2012 Aug; 77 Suppl 1():84-6. PubMed ID: 22939493
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnosis and treatment of non-alcoholic fatty liver disease].
    Su W; Cao H; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Sep; 22(9):705-7. PubMed ID: 25647847
    [No Abstract]   [Full Text] [Related]  

  • 19. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
    ; ;
    J Hepatol; 2016 Jun; 64(6):1388-402. PubMed ID: 27062661
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.